Cannabinoid Hyperemesis SyndromeEarly Phase 1NCT07726069
Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department
A Early Phase 1 study testing Haloperidol in people with Cannabinoid Hyperemesis Syndrome, run by University of Illinois Chicago at 1 site in United States.
Trial summary
Patients diagnosed with cannabinoid hyperemesis syndrome that are safe for discharge from the emergency department will be sent an outpatient prescription for haloperidol to be used as needed at home. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cannabinoid Hyperemesis Syndrome
- What is being tested?
- Haloperidol
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- Nov 2026to Jan 2028
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Patients must meet ALL of the following criteria:
- Age ≥ 18 years
- Primary ED complaints of acute or episodic nausea, vomiting, and/or abdominal pain
- Self reported frequent cannabis use
- Patients must meet at least TWO of the following criteria:
- History of recurrent, cyclical episodes of severe nausea and vomiting
- Self-reported temporary symptom relief with hot showers or baths
- Symptom onset or exacerbation following cannabis consumption
Who cannot join
- Patients with imaging or lab findings suggestive of an alternative etiology that would explain their symptoms
- Already on dopamine agonist/antagonist therapy for another condition
- Parkinson's disease
- Lewy body dementia
- Men with QTc > 450
- Women with QTc > 460
Show all 13Show fewer
- Patients with documented allergy to haloperidol
- Patients with known functional prolactinomas
- Patients who are breastfeeding
- Patients under the age of 18
- Patients who are pregnant
- Patients who are in the prison system
- Patients who are unable to consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of Illinois Hospital
Chicago, Illinois, 60612
Mason A Bartman, MD, 8178972205, mbartman@uic.edu
Wesley Eilbert, MD, 6302944225, weilbert@uic.edu
About this study
Patients diagnosed with cannabinoid hyperemesis syndrome that are safe for discharge from the emergency department will be sent an outpatient prescription for haloperidol to be used as needed at home. The study goal is to see if having this medication available helps to prevent return emergency department visits for recurrent or persistent symptoms.
Read the detailed description
Cannabinoid hyperemesis syndrome is a relatively new syndrome characterized by nausea, vomiting, and abdominal pain in the setting of excessive cannabis use. This clinical entity has become increasingly prevalent as the concentration of THC has increased in marijuana products over the past several decades. The symptoms have been treated successfully with several medications however the most efficacious appears to be dopamine antagonists such as haloperidol and droperidol. These dopamine antagonists have been used safely and successfully in the inpatient and emergency department settings to decrease the frequency and intensity of nausea, vomiting, and abdominal pain in patients suffering from cannabinoid hyperemesis syndrome. The investigators plan to evaluate haloperidol, a dopamine antagonist available as an oral formulation, as an option for outpatient management of these symptoms.
- Conditions
- Cannabinoid Hyperemesis Syndrome
- Being tested
- Haloperidol
- Keywords
- chs, cannabinoid hyperemesis syndrome, haldol, haloperidol
- Medical subject headings
- Cannabinoid Hyperemesis Syndrome, Chediak-Higashi Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HaloperidolDrug
This intervention involves providing patients an outpatient prescription for as needed haloperidol to attempt to control symptoms of cannabinoid hyperemesis and to attempt to prevent return to the emergency department for that reason.
| Study group | Role | What they receive |
|---|---|---|
| Patients who will receive haloperidol | Experimental | Patients in this arm of the study will receive haloperidol to be used as needed on an outpatient basis Receives: Drug: Haloperidol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of return to the emergency department
The investigators plan to measure the percentage of people who return to the emergency department for recurrence of symptoms attributable to cannabinoid hyperemesis syndrome
Measured: 1 month
Secondary outcomes (2)
Improvement in symptoms
The investigators plan to report patient reported change in symptoms attributable to cannabinoid hyperemesis syndrome. The subjects will report change in their symptoms via a 5 point likert scale with 1 being no change in symptoms at all and 5 being complete resolution of symptoms.
Measured: 1 month
Medication side effects
The investigators plan to report the rate of patient reported side effects that are considered attributable to cannabinoid hyperemesis syndrome
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2026
- Study startNov 2026 (estimated)
- Primary completionJan 2028 (estimated)
- Study completionJan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cannabinoid Hyperemesis SyndromeStudies of the same condition, open and under way.
- More trials run by University of Illinois ChicagoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Illinois Chicago
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mason Bartman, University of Illinois Chicago
- Investigators
- Wesley Eilbert, MD, Principal investigator, University of Illinois Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07726069
- Sponsor's protocol ID
- 2026-0693
- Status last verified
- Aug 2026
- First submitted
- 21 Jul 2026
- Last updated
- 1 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: The investigators don't need to share IPD with anyone outside of investigators in this clinical trial to complete this trial.
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department
- ClinicalTrials.gov ID
- NCT07726069
- Acronym / sponsor ID
- 2026-0693
- Conditions
- Cannabinoid Hyperemesis Syndrome
- Keywords
- chs, cannabinoid hyperemesis syndrome, haldol, haloperidol
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University of Illinois ChicagoUniversity, hospital or other
- Study start
- Nov 2026 (estimated)
- Primary completion
- Jan 2028 (estimated)
- Study completion
- Jan 2028 (estimated)
- First posted
- 24 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients diagnosed with cannabinoid hyperemesis syndrome that are safe for discharge from the emergency department will be sent an outpatient prescription for haloperidol to be used as needed at home. The study goal is to see if having this medication available helps to prevent return emergency department visits for recurrent or persistent symptoms.
Detailed description
Cannabinoid hyperemesis syndrome is a relatively new syndrome characterized by nausea, vomiting, and abdominal pain in the setting of excessive cannabis use. This clinical entity has become increasingly prevalent as the concentration of THC has increased in marijuana products over the past several decades. The symptoms have been treated successfully with several medications however the most efficacious appears to be dopamine antagonists such as haloperidol and droperidol. These dopamine antagonists have been used safely and successfully in the inpatient and emergency department settings to decrease the frequency and intensity of nausea, vomiting, and abdominal pain in patients suffering from cannabinoid hyperemesis syndrome. The investigators plan to evaluate haloperidol, a dopamine antagonist available as an oral formulation, as an option for outpatient management of these symptoms.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients who will receive haloperidol | Experimental | Drug: HaloperidolPatients in this arm of the study will receive haloperidol to be used as needed on an outpatient basis |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Age ≥ 18 years
- Primary ED complaints of acute or episodic nausea, vomiting, and/or abdominal pain
- Self reported frequent cannabis use
- History of recurrent, cyclical episodes of severe nausea and vomiting
- Self-reported temporary symptom relief with hot showers or baths
Key exclusion criteria (13 listed)
- Patients with imaging or lab findings suggestive of an alternative etiology that would explain their symptoms
- Already on dopamine agonist/antagonist therapy for another condition
- Parkinson's disease
- Lewy body dementia
- Men with QTc > 450
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HaloperidolThis intervention involves providing patients an outpatient prescription for as needed haloperidol to attempt to control symptoms of cannabinoid hyperemesis and to attempt to prevent return to the emergency department for that reason. | Drug | Patients who will receive haloperidol |
Primary outcome
Rate of return to the emergency department
Time frame: 1 month
The investigators plan to measure the percentage of people who return to the emergency department for recurrence of symptoms attributable to cannabinoid hyperemesis syndrome
2 secondary outcomes
Improvement in symptoms
Time frame: 1 month
Medication side effects
Time frame: 1 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2026.
- Individual participant dataSharing planned: No. The investigators don't need to share IPD with anyone outside of investigators in this clinical trial to complete this trial.
Related trials for Cannabinoid Hyperemesis Syndrome
Enrolling by invitationObservational study
Body Surface Gastric Mapping to Evaluate Patients With Upper Gastrointestinal Symptoms and Controls
Motility Disorder, Gastroparesis
RecruitingObservational study
Cannabinoid Hyperemesis Syndrome. Prospective Multicenter Study of Patients Admitted to Adult Emergency Departments in Maine-et-Loire.
D000096704, Cannabinoid Hyperemesis Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Wesley Eilbert, MD principal investigator
University of Illinois Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Haloperidol in people with Cannabinoid Hyperemesis Syndrome, run by University of Illinois Chicago at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 1 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mason A Bartman, MD (8178972205, mbartman@uic.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of return to the emergency department (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2026.